Summary
This article discusses the results from the Assessment of Weekly Administration of LY2189265 in Diabetes-6 [AWARD-6; NCT01624259] trial, which show that once-weekly dulaglutide provides glycemic control that is noninferior to once-daily liraglutide with a similar safety and tolerability profile.
- Diabetes & Endocrinology Clinical Trials
- Hyperglycemia/Hypoglycemia
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- Diabetes & Endocrinology Clinical Trials
- Hyperglycemia/Hypoglycemia
- Diabetes Mellitus
- © 2014 MD Conference Express®
Tools
Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM
Permalink:
Table of contents
Cited By...
- No citing articles found.